Education
About Us
Working with TipRanks
Follow Us
EnBio Holdings, Inc. (JP:6092)
:6092
6092 Stock Chart & Stats
¥598.00
-¥2.00(-0.33%)
At close: 4:00 PM EST
¥598.00
-¥2.00(-0.33%)
Day’s Range― - ―
52-Week Range¥500.00 - ¥746.00
Previous CloseN/A
Volume5.80K
Average Volume (3M)25.91K
Market Cap
¥4.99B
Enterprise Value¥11.48B
Total Cash (Recent Filing)¥3.19B
Total Debt (Recent Filing)¥10.28B
Price to Earnings (P/E)―
Beta0.61
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.54%
Share Statistics
EPS (TTM)-75.25
Shares Outstanding8,175,200
10 Day Avg. Volume21,320
30 Day Avg. Volume25,910
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)0.53
Price to Sales (P/S)0.45
P/FCF Ratio-3.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthDouble-digit revenue growth across the most recent year demonstrates durable demand for the company’s offerings and organic expansion of sales. Sustained top-line momentum supports capacity to invest in product development, scale fixed costs, and improve long-term operating leverage.
Healthy Operating MarginsRelatively strong EBIT and EBITDA margins indicate efficient core operations and cost control versus peers. Persistent mid-single-digit operating margins create a buffer against revenue cyclicalities and provide potential to convert improved scale into higher and more sustainable cash generation over time.
Balanced Capital StructureA debt-to-equity around 1.1 with an equity ratio above 40% signals a measured leverage profile that can fund growth while preserving flexibility. This balanced structure supports ongoing capital investment and lowers refinancing risk, important for steady operations through multi-quarter cycles.
Bears Say
Negative Free Cash FlowFree cash flow turned negative due to elevated capital expenditures, reducing financial flexibility. Persistently negative FCF limits the company’s ability to self-fund growth, deleverage, or return capital; unless capex normalizes, this can strain liquidity and strategic optionality over months.
Weak Cash ConversionAn operating cash flow to net income ratio near 0.05 signals poor conversion of accounting profits into cash. Structural conversion inefficiencies can amplify funding needs, increase reliance on external capital, and constrain investment or dividend capacity across multiple quarters if not improved.
Low Return On EquityA sub-5% ROE indicates limited effectiveness in generating shareholder returns from equity capital. Over a multi-quarter horizon, low ROE can reflect competitive pressures or suboptimal asset allocation, making it harder to justify reinvestment and reducing long-term attractiveness to capital providers.
EnBio Holdings, Inc. News
6092 FAQ
What was EnBio Holdings, Inc.’s price range in the past 12 months?
EnBio Holdings, Inc. lowest stock price was ¥500.00 and its highest was ¥746.00 in the past 12 months.
What is EnBio Holdings, Inc.’s market cap?
EnBio Holdings, Inc.’s market cap is ¥4.99B.
When is EnBio Holdings, Inc.’s upcoming earnings report date?
EnBio Holdings, Inc.’s upcoming earnings report date is May 20, 2026 which is in 92 days.
How were EnBio Holdings, Inc.’s earnings last quarter?
EnBio Holdings, Inc. released its earnings results on Feb 13, 2026. The company reported -¥75.25 earnings per share for the quarter, missing the consensus estimate of N/A by -¥75.25.
Is EnBio Holdings, Inc. overvalued?
According to Wall Street analysts EnBio Holdings, Inc.’s price is currently Overvalued.
Does EnBio Holdings, Inc. pay dividends?
EnBio Holdings, Inc. pays a Annually dividend of ¥9 which represents an annual dividend yield of 1.54%. See more information on EnBio Holdings, Inc. dividends here
What is EnBio Holdings, Inc.’s EPS estimate?
EnBio Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does EnBio Holdings, Inc. have?
EnBio Holdings, Inc. has 8,175,200 shares outstanding.
What happened to EnBio Holdings, Inc.’s price movement after its last earnings report?
EnBio Holdings, Inc. reported an EPS of -¥75.25 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.165%.
Which hedge fund is a major shareholder of EnBio Holdings, Inc.?
Currently, no hedge funds are holding shares in JP:6092
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
EnBio Holdings, Inc.
EnBio Holdings Co., Ltd. engages in soil and groundwater contamination, and renewable energy businesses in Japan. It imports and sells equipment, materials, and cleaning agents; and purchases, sells, and leases contaminated land. The company is also involved in solar power; biomass power generation; renewable energy power generation; water resource development; and ethical consumption promotion businesses. EnBio Holdings Co., Ltd. was incorporated in 1999 and is headquartered in Tokyo, Japan.
Technical Analysis
Hikari Business Form Co., Ltd.
―
CRESTEC Inc.
―
Sougou Shouken Co., Ltd.
―
Sun Messe Co., Ltd.
―
Mitsumura Printing Co., Ltd.
―